Amazon ( AMZN ) actually ended a successful year with its Q4 2025 figures . However, the market reacted negatively, particularly in view of the CapEx forecast for FY 2026, triggering a sell-off. Following this reaction, the share price is now**My articles represent my opinion only and in no way constitute professional investment advice. It is the responsibility of the reader to conduct their due diligence and seek investment advice from a licensed professional before making any investment decisions.**Analys ...

Company Performance - Ginkgo Bioworks Holdings, Inc. (DNA) closed at $9.23, down 9.06% from the previous trading session, underperforming the S&P 500's daily loss of 0.33% [1] - Over the past month, the company's shares gained 6.17%, outperforming the Medical sector's loss of 1.02% and the S&P 500's unchanged performance [1] Earnings Projections - The upcoming earnings release is projected to show an earnings per share (EPS) of -$1.8, reflecting a 1.1% increase from the same quarter last year [2] - Revenue is anticipated to be $37 million, indicating a 15.62% decrease from the same quarter last year [2] Annual Estimates - For the annual period, the Zacks Consensus Estimates predict an EPS of -$5.94 and revenue of $173 million, representing changes of +42.66% and -23.8% from the previous year, respectively [3] - Recent changes to analyst estimates suggest a shifting landscape in near-term business trends, with positive alterations indicating analyst optimism [3] Zacks Rank and Industry Performance - The Zacks Rank system, which ranges from 1 (Strong Buy) to 5 (Strong Sell), has a strong track record, with stocks rated 1 producing an average annual return of +25% since 1988 [5] - Ginkgo Bioworks currently holds a Zacks Rank of 3 (Hold), with the consensus EPS estimate remaining unchanged over the last 30 days [5] - The Medical - Biomedical and Genetics industry, part of the Medical sector, holds a Zacks Industry Rank of 86, placing it in the top 36% of over 250 industries [6]

Core Insights - The report highlights the transition of AI Agents from tools to partners, marking a new era in digital economy [2][4] - The AI Agent market is projected to grow significantly, with an expected increase from $8.2 billion in 2023 to $14.1 billion by 2033, representing a growth rate of 68.18% [4] - The report emphasizes the importance of regional collaboration and ecosystem construction in accelerating AI industry transformation in China [11][12] Section Summaries 1. Focus of the Report: AI Agents Transitioning to Partners - The evolution of AI technology can be categorized into three stages, with AI Agents now entering a phase of explosive growth [4] - The AI Agent market is expected to grow from $12 billion in 2023 to $20.55 billion by 2033, indicating a compound annual growth rate (CAGR) of 5.5% [4] 2. China Dynamics: Accelerating AI Industry Transformation - Central government policies are increasingly focused on integrating AI into various sectors to promote high-quality development [11][12] - Local governments are implementing tailored policies to foster AI integration, leveraging regional strengths [12] - Significant capital inflows into leading AI companies reflect market confidence in technological advancements [12] 3. U.S. Dynamics: Intensifying Capital and Commercialization - Major AI companies are attracting substantial investments, with valuations and funding targets on the rise [13][14] - Strategic investments by tech giants are enhancing their integration with key AI firms, reinforcing their positions in the industry [13] - The competition in AI commercialization is heating up, with diverse revenue models being explored [14] 4. European Dynamics: Balancing Regulation and Industry Competitiveness - The UK is collaborating with tech giants to develop frameworks addressing new digital threats like deepfakes [16] - Regulatory bodies are investigating the misuse risks of generative AI applications, focusing on data protection and online safety [17] - The EU is initiating investigations to ensure fair competition in the AI sector, emphasizing interoperability and data access [17] 5. Other Countries: Strengthening AI Infrastructure - AI demand is driving a supercycle in the storage industry, with South Korean firms enhancing their market positions [18] - Storage chip prices are rising due to AI needs, leading to record performances for major manufacturers [18] - The global semiconductor landscape is shifting, with a focus on diversifying supply chains to meet AI demands [19]

2026年02月09日 联系人 王雪蓉 A0230523070003 wangxr@swsresearch.com 申万宏源研究微信服务 量子互联网可扩展性进步; 脑机迈入商业化阶段 未来产业周报第 9 期（2026/2/1-2026/2/7） 相关研究 《lonQ 收购整合量子制造; 星星地激光通信突破 周报第８期 (2026/1/25- 2026/1/31) 》 2026/02/01 《双重码降低量子纠错开销，风电 a 年提升制氢效率 -未来产业信 报第 7 期 (2026/1/18- 2026/1/24)》 2026/01/25 证券分析师 王雪蓉 A0230523070003 wangxr@swsresearch.com 年瑾瑾 A0230524100002 mujj@swsresearch.com 陆灏川 A0230520080001 luhc@swsresearch.com 刘雅婧 A0230521080001 liuyj@swsresearch.com 刘洋 A0230513050006 liuyang2@swsresearch.com 曹峥 A0230525040002 caozhenq@sw ...

2026 年 02 月 09 日 量子互联网可扩展性进步；侵入式 脑机迈入商业化阶段 ——未来产业周报第 9 期（2026/2/1-2026/2/7） 相关研究 《IonQ 收购整合量子制造；中科卫 星星地激光通信突破——未来产业 周报第 8 期（2026/1/25- 2026/1/31）》 2026/02/01 《双重码降低量子纠错开销，风电 直连提升制氢效率——未来产业周 报第 7 期（2026/1/18- 2026/1/24）》 2026/01/25 证券分析师 王雪蓉 A0230523070003 wangxr@swsresearch.com 牟瑾瑾 A0230524100002 mujj@swsresearch.com 陆灏川 A0230520080001 luhc@swsresearch.com 刘雅婧 A0230521080001 liuyj@swsresearch.com 刘洋 A0230513050006 liuyang2@swsresearch.com 曹峥 A0230525040002 caozheng@swsresearch.com 陈晴华 A0230525100001 chenqh@ ...

Core Insights - Ginkgo Bioworks, in collaboration with OpenAI, has developed an AI system that autonomously designs and executes biological experiments, achieving a 40% reduction in cell-free protein synthesis reaction costs compared to the current state of the art [1][4][7] Group 1: AI and Autonomous Lab Integration - The study showcases a practical application of Ginkgo's autonomous lab, utilizing OpenAI's GPT-5 model to design, execute, and analyze experiments in a closed-loop workflow [3][5] - The autonomous lab executed over 36,000 experimental conditions across six iterative cycles, generating nearly 150,000 experimental data points [5][7] - Human involvement was limited to reagent preparation and system oversight, while the AI handled experimental design and data interpretation [5][6] Group 2: Cost Reduction and Efficiency - The autonomous lab produced a benchmark protein, superfolder green fluorescent protein (sfGFP), at a cost of $422 per gram, down from the previously reported $698 per gram, marking a 40% cost reduction [4][7] - The integration of AI in the lab is expected to lead to more experiments being conducted, as lower reagent costs will facilitate increased data generation and scientific progress [4][8] Group 3: Commercial Potential - Ginkgo is now offering the AI-optimized reaction mix for sale in its reagents store, indicating the commercial viability of AI-driven scientific advancements [7][8] - The Pydantic model used for validating experiments will be released as open source, further promoting transparency and collaboration in scientific research [6][8]

Company Performance - Ginkgo Bioworks Holdings, Inc. (DNA) experienced a decline of 5.92% in its latest trading session, closing at $8.27, which underperformed compared to the S&P 500's loss of 0.51% [1] - Over the past month, the company's shares have decreased by 4.14%, lagging behind the Medical sector's gain of 3.1% and the S&P 500's increase of 0.93% [1] Upcoming Earnings - Analysts anticipate that Ginkgo Bioworks will report earnings of -$1.8 per share, indicating a year-over-year growth of 1.1%. Revenue is projected to be $37 million, reflecting a 15.62% decline from the same quarter last year [2] - For the full year, the Zacks Consensus Estimates predict earnings of -$5.94 per share and revenue of $173 million, representing changes of +42.66% in earnings and 0% in revenue compared to the previous year [3] Analyst Estimates and Rankings - Recent changes to analyst estimates for Ginkgo Bioworks are important as they reflect short-term business trends, with positive revisions indicating a favorable business outlook [4] - The Zacks Rank system, which incorporates these estimate changes, currently assigns Ginkgo Bioworks a rank of 3 (Hold), with the consensus EPS estimate remaining steady over the past month [6] Industry Context - Ginkgo Bioworks operates within the Medical - Biomedical and Genetics industry, which holds a Zacks Industry Rank of 90, placing it in the top 37% of over 250 industries [7] - Research indicates that industries in the top 50% outperform those in the bottom half by a factor of 2 to 1 [7]

Company Performance - Ginkgo Bioworks Holdings, Inc. (DNA) closed at $9.31, reflecting a -1.27% change from the previous day, underperforming the S&P 500 which had a daily loss of 0.13% [1] - Over the last month, the company's shares increased by 13.48%, outperforming the Medical sector's decline of 2.41% and the S&P 500's gain of 0.78% [1] Earnings Estimates - The upcoming earnings release is anticipated, with an expected EPS of -$1.8, indicating a 1.1% growth compared to the same quarter last year [2] - Revenue is projected at $37 million, reflecting a 15.62% decrease from the equivalent quarter last year [2] - For the full year, earnings are estimated at -$5.94 per share and revenue at $173 million, showing a 42.66% increase in earnings but no change in revenue from the previous year [3] Analyst Sentiment - Recent changes to analyst estimates are crucial for investors, as they reflect short-term business trends and can indicate analyst optimism regarding profitability [3] - The Zacks Rank system, which ranges from 1 (Strong Buy) to 5 (Strong Sell), currently ranks Ginkgo Bioworks Holdings, Inc. at 3 (Hold) [5] Industry Context - The Medical - Biomedical and Genetics industry, part of the Medical sector, holds a Zacks Industry Rank of 90, placing it in the top 37% of over 250 industries [6] - The Zacks Industry Rank assesses the strength of industry groups based on the average Zacks Rank of individual stocks, with top-rated industries outperforming lower-rated ones by a factor of 2 to 1 [6]

Company Performance - Ginkgo Bioworks Holdings, Inc. closed at $10.02, reflecting a -6.36% change from the previous day, underperforming the S&P 500's 0.03% gain [1] - Over the past month, shares of Ginkgo Bioworks have increased by 20.09%, outperforming the Medical sector's loss of 0.01% and the S&P 500's gain of 0.6% [1] Earnings Expectations - Analysts expect Ginkgo Bioworks to report earnings of -$1.8 per share, indicating a year-over-year growth of 1.1% [2] - The consensus estimate for revenue is $37 million, representing a 15.62% decrease compared to the same quarter of the previous year [2] Annual Forecast - For the entire year, Zacks Consensus Estimates predict earnings of -$5.94 per share and revenue of $173 million, showing changes of +42.66% and 0%, respectively, compared to the previous year [3] Analyst Sentiment - Recent changes to analyst estimates for Ginkgo Bioworks reflect evolving short-term business trends, with upward revisions indicating analysts' positive outlook on the company's operations [4] - The Zacks Rank system, which incorporates these estimate changes, currently ranks Ginkgo Bioworks as 3 (Hold) [6] Industry Context - Ginkgo Bioworks operates within the Medical - Biomedical and Genetics industry, which ranks in the top 36% of all industries according to the Zacks Industry Rank [7] - The Zacks Industry Rank assesses the strength of industry groups, with top-rated industries outperforming lower-rated ones by a factor of 2 to 1 [7]

Company Performance - Ginkgo Bioworks Holdings, Inc. (DNA) closed at $9.85, reflecting a +2.39% change from the previous day, outperforming the S&P 500's daily loss of 0.53% [1] - Over the past month, the company's shares have gained 16.47%, significantly exceeding the Medical sector's gain of 0.09% and the S&P 500's gain of 2.06% [1] Earnings Projections - The upcoming earnings disclosure is projected to show earnings per share (EPS) of -$1.8, which is a 1.1% increase from the same quarter last year [2] - Revenue is anticipated to be $37 million, indicating a 15.62% decrease from the same quarter last year [2] Full-Year Estimates - The full-year Zacks Consensus Estimates predict earnings of -$5.94 per share and revenue of $173 million, representing year-over-year changes of +42.66% for earnings and 0% for revenue [3] - Recent changes to analyst estimates for Ginkgo Bioworks should be monitored as they reflect evolving short-term business trends [3] Zacks Rank and Industry Performance - Ginkgo Bioworks currently holds a Zacks Rank of 3 (Hold), with no changes in the Zacks Consensus EPS estimate over the past month [5] - The Medical - Biomedical and Genetics industry, part of the Medical sector, has a Zacks Industry Rank of 96, placing it in the top 40% of over 250 industries [6]